Physician profile
Long Cao
NPI 1124281118
$5,450.04
in general payments reported to CMS, 2019-2025
32 companies · $820 in 2025
The $820 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $520 · 2020: $147 · 2021: $571 · 2022: $1,878 · 2023: $867 · 2024: $648 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,335.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $732.46 | 2019-2025 | Triclip, Cardiomems, Perclose Prostyle |
| Novartis Pharmaceuticals Corporation | $640.29 | 2019-2025 | |
| Boston Scientific Corporation | $550.66 | 2019-2025 | Watchman Flx, Watchman Access System, Bodyguardian |
| Angiodynamics, INC. | $465.06 | 2022 | |
| Amgen INC. | $353.65 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $344.36 | 2019-2024 | Lifevest |
| Abiomed | $338.70 | 2022-2024 | Impella |
| Irhythm Technologies, INC. | $321.60 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Medtronic, INC. | $250.46 | 2023-2025 | Valiant Captivia, Linq II, Corevalve Evolut R |
| Impulse Dynamics (USA) INC. | $223.19 | 2022-2024 | Optimizer |
| Merck Sharp & Dohme LLC | $203.74 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $142.29 | 2022-2024 | Xarelto |
| Novo Nordisk INC | $126.34 | 2022-2025 | Wegovy |
| Althera Pharmaceuticals LLC | $98.72 | 2021-2022 | |
| Cardiva Medical, INC. | $77.34 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $74.85 | 2025 | |
| Edwards Lifesciences Corporation | $73.17 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $61.29 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $51.82 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $51.00 | 2019-2022 | |
| Pfizer INC. | $41.04 | 2022-2024 | |
| Kowa Pharmaceuticals America, INC. | $31.52 | 2019-2021 | |
| W. L. Gore & Associates, INC. | $26.99 | 2025 | Gore Cardioform Septal Occluder |
| Atricure, INC. | $25.88 | 2023 | |
| Preventice Services, LLC | $25.85 | 2021 | |
| Cvrx, INC. | $24.77 | 2024 | Barostim Neo System |
| Sensible Medical Innovations INC | $21.85 | 2023 | Reds System |
| E.R. Squibb & Sons, L.L.C. | $15.46 | 2024 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.57 | 2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.33 | 2021 | |
| Altathera Pharmaceuticals LLC | $13.73 | 2023 | Sotalol Hydrochloride |
| Allergan, INC. | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Long Cao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.